Adipose Tissue and Serum Inflammation in GH Deficiency

NCT03500913 | Completed

• 2 other identifiers: AAAP39501R01DK110771-01A1
• Study Type: observational
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

This study will examine adipose tissue inflammation and adipokine expression and serum markers of inflammation and adipokine levels in patients with growth hormone (GH) deficiency before and after treatment.

Conditions

Growth Hormone Deficiency

Keywords

Growth Hormone Deficiency; Adipose Tissue; Inflammation

Outcome Measures

Primary Outcomes (1)

• Visceral Adipose Tissue (VAT) mass

  Visceral adipose tissue mass as measured by tota body magnetic resonance imaging

  Baseline to 12 months of GH therapy

Secondary Outcomes (12)

• Intra-hepatic lipid level

  Baseline to 12 months of GH therapy

• Skeletal Muscle Mass

  Baseline to 12 months of GH therapy

• Total body fat

  Baseline to 12 months of GH therapy

• Resting metabolic rate

  Baseline to 12 months of GH therapy

• Relative gene expression of CD68 gene

  Baseline to 12 months of GH therapy

Study Arms (2)

Adults with growth hormone deficiency

Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.

Drug: Growth Hormone

Control group

Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).

Interventions

Growth Hormone DRUG

Patients will receive growth hormone replacement therapy as per standard clinical care during this study.

Also known as: GH

Adults with growth hormone deficiency

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Potential subjects include all those who present to our Neuroendocrine Unit for therapy of GH deficiency or who are followed in our unit and have GH deficiency and are planning to initiate a therapy. Subjects will be those with central adiposity. We expect are study group to be approximately half women and reflect the ethnic mix of our study populations of our other pituitary tumor studies, which is primarily drawn from the New York Metropolitan area.

You may qualify if:

• Males or females age ≥18 years with diagnosis of GH deficiency that is Adult Onset, either alone or associated with multiple pituitary hormone deficiencies and due to pituitary disease,hypothalamic disease, surgery, radiation therapy or Childhood Onset due to congenital, genetic, acquired, or idiopathic causes.
• Diagnosis of GH deficiency defined by: insulin tolerance test or glucagon test: peak growth hormone response \< 3 ng/ml or 3 or more pituitary hormone deficiencies and IGF-1 standard deviation score \< -2.0
• No history of diabetes mellitus and fasting blood sugar at screening visit ≤ 120 mg/dl.
• If patients have undergone surgical resection of a pituitary adenoma, a minimum of 12 months must have elapsed post surgery prior to enrollment and tumor will be demonstrated to be unchanged for 12 months or longer since surgery.
• May have a history of radiotherapy, but they must have completed their course of radiotherapy more than 3 months prior to study screening.
• If prior GH therapy must have not received prior growth hormone replacement therapy in 310 the 6 months prior to screening.
• Stable pituitary hormone supplements (x 3 months) prior to baseline visit and normal levels of free thyroxine, testosterone in males and normal adrenal function if not on replacement therapy.
• If female, a. Not pregnant (as evidenced by a negative serum pregnancy test) or lactating and b. If of childbearing potential, agrees to use a medically acceptable form of contraception (such as oral, implantable, or barrier contraception) from the time of screening, for the duration of the study, and for at least one month after study discontinuation or completion. Childbearing potential is defined as women who are not surgically sterile or not at least one year postmenopausal.
• Sign and date an informed consent document indicating that the subject (or legally acceptable representative) has been informed of and agrees to all pertinent aspects of the trial.

You may not qualify if:

• Have other conditions that may result in abnormal GH and/or IGF-I concentrations (e.g., severe hepatic disease, severe renal disease, malnutrition, treatment with levodopa).
• Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≥ 2 x upper limit of normal or clinically significant hepatic disease or renal impairment defined as creatinine \> 1.5x upper normal.
• Have a pituitary adenoma with a distance to the optic chiasm of 5 mm or less, confirmed by a recent MRI scan (within two months prior to the screening visit).
• Pituitary tumor growth within the 12 months prior to study entry.
• GH therapy within 6 months of screening.
• Diabetes mellitus.
• History of acromegaly.
• History of active Cushing's disease within 24 months of screening
• Visual field defects or other neurological symptoms due to current tumor mass compression.
• Have known or suspected drug or alcohol abuse.
• Have received an investigational medication within four weeks prior to Screening or is scheduled to receive any investigational medication during the study.
• Do not have the ability to fully comprehend the nature of the study, to follow instructions, cooperate with study procedures, and/or are unable to adhere to the visit scheduled outlined in the protocol.
• Have other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
• History of a malignancy other than squamous or basal cell skin carcinoma that has been excised or intracranial malignant tumors or leukemia within 5 years of screening.
• Patients who have a known hypersensitivity to growth hormone therapy

Sponsors & Collaborators

• Columbia University: lead
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): collaborator

Study Sites (1)

Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center

New York, New York, 10032, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

1. Peripheral venous blood 2. Subcutaneous adipose tissue

MeSH Terms

Conditions

Dwarfism, Pituitary; Inflammation

Interventions

Growth Hormone

Condition Hierarchy (Ancestors)

Dwarfism; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Bone Diseases, Endocrine; Hypopituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Anterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Pamela U. Freda, MD

  Columbia University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medicine

Study Record Dates

• First Submitted: April 10, 2018
• First Posted: April 18, 2018
• Study Start: May 19, 2019
• Primary Completion: February 12, 2020
• Study Completion: February 20, 2020
• Last Updated: May 13, 2025

Record last verified: 2025-05

Locations

US (1)